RxDoctor Payments Data

Mark Beamer, MD

Family Medicine · Belhaven, NCNPI 1053426346

Payments from drug & device makers

$10,893in general payments, 2019–2025

Across 627 payments — averaging $17.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • Amgen$2K
  • AstraZeneca$1K
  • GSK$1K
  • AbbVie$653
  • Pfizer$531
  • plus $4K from 31 others

What the payments were for

  • Food & beverage$10,843100%
  • Education$400%
  • Other$100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,893 in reported general payments places this provider in the 90th percentile of 3,444 family medicine providers in North Carolina.

See all family medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$196,555
Medicare patients
589
Services billed
7,436

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide143$207,080
FarxigaDapagliflozin Propanediol176$126,813
EliquisApixaban113$104,816
MounjaroTirzepatide83$90,494
Trelegy ElliptaFluticasone/Umeclidin/Vilanter91$79,513
XareltoRivaroxaban68$56,619
JardianceEmpagliflozin31$49,724
JanuviaSitagliptin Phosphate39$42,655
MyrbetriqMirabegron56$34,066
EntrestoSacubitril/Valsartan43$29,540
TrulicityDulaglutide20$28,574
KerendiaFinerenone14$26,861
Breztri AerosphereBudesonide/Glycopyr/Formoterol34$21,290
Tresiba Flextouch U-200Insulin Degludec20$13,523
Bydureon BciseExenatide Microspheres14$13,235

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,960$207,080143 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$1,312$153,589225 claims
Lilly USA, LLCMounjaro, Trulicity$462$119,068103 claims
PfizerEliquis$531$104,816113 claims
GSKTrelegy Ellipta$1,012$79,51391 claims
Boehringer IngelheimJardiance, Spiriva Respimat$179$58,96850 claims
MerckJanuvia, Janumet, Belsomra$168$57,91062 claims
Johnson & JohnsonXarelto$319$56,61968 claims
Astellas Pharma US IncMyrbetriq$176$34,06656 claims
NovartisEntresto$161$29,54043 claims
BayerKerendia$169$26,86114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,444 family medicine providers in North Carolina.

Other family medicine in Belhaven

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →